Recently, Sanyou Biopharmaceuticals Co., Ltd. (hereinafter
referred to as Sanyou) and Hangzhou Zhongmei Huadong Pharmaceutical Co.,
Ltd, a wholly-owned subsidiary of Huadong Medicine Co., Ltd.
(SZ.000963) (hereinafter referred to as Huadong Medicine), signed a
license agreement for a collaboratively developed therapeutic biological
product.
This license is a continuation of the strategic partnership
agreement signed by both parties in Nov. 2020. As a cutting-edge
high-tech biotechnology enterprise dedicated to the R&D and services
of innovative biopharmaceuticals, Sanyou has established a
world-leading core technology platform for integrated R&D and
preclinical development of innovative biological drugs, along with a
world-class "super-trillion innovative biologics discovery platform".
Huadong Medicine, on the other hand, is an innovative international
pharmaceutical company driven by scientific R&D and technological
innovation, which possesses years of technical expertise, clinical
insights, and integrated commercial capabilities in the therapeutic area
of oncology. The collaboration between the two parties is based on the
complementary strengths of both parties. By leveraging their respective
advantages, both parties will work hand in hand to make contributions to
the advancement of innovative biopharmaceuticals.
Dr. Jeffery Liu, Chief Scientific Officer of Huadong Medicine,
stated, "Since embarking on our innovative transformation, Huadong
Medicine has been consistently increasing its R&D investments in the
therapeutic area of oncology. We have been enriching our pipeline
layout of innovative drug R&D through a combination of independent
R&D, collaborative and commissioned development, and pipeline
license-in. We are delighted to further collaborate with Sanyou, as this
agreement marks an important milestone in deepening our partnership. We
hope that this project can progress into clinical stages in the near
future, benefiting patients in need."
"We are greatly honored to establish a further strategic
partnership with Huadong Medicine," stated Dr. Guojun Lang, CEO of
Sanyou. "As an international pharmaceutical company, Huadong Medicine
has been committed to strengthening its innovation and influence in the
therapeutic area of oncology and has solid strength in transforming
innovative projects into commercialized leading drugs. The signing of
this agreement signifies the milestone achievement in the development of
this innovative drug candidate. In the future, Sanyou will continue to
exert our utmost efforts to support our partners in accelerating the
innovative drug R&D process."
About Huadong Medicine: Huadong Medicine Co., Ltd. (SZ.000963)
was founded in 1993, with its headquarters located in Hangzhou,
Zhejiang. Adhering to the company value of "Science Driven, Patient
Centered", Huadong Medicine has gone through over 20 years of
development, and has established a business presence covering the entire
pharmaceutical industry chain, with four major business segments:
pharmaceutical industry, pharmaceutical commerce, aesthetic medicine,
and industrial microorganism, and has grown into a large comprehensive
pharmaceutical listed company that integrates pharmaceutical R&D,
manufacturing, and distribution. In 2022, Huadong Medicine achieved a
revenue of 37.715 billion yuan. With a current employee count exceeding
ten thousand, the company possesses extensive commercial coverage and
strong marketing capabilities.
About Sanyou: Sanyou Biopharmaceuticals Co., Ltd. is a
world-leading high-tech biotechnology enterprise focusing on R&D and
services of innovative biological drugs. Sanyou is committed to bridge
drug R&D and all-life-cycle manufacture supply chain, and has built
the 4C business patterns that integrate "differentiated CRO, integrated
CDO, innovative CPO and characteristic CRS”, to accomplish the mission
“to make it easy to discover innovative biological drugs anywhere”.
Sanyou has established an integrated innovative biological drug
R&D laboratory of twenty thousand square meters with advanced
facilities, and has built three industry-leading innovative technology
platforms featured by “super-trillion, integration, and intelligence" ,
which are comprised of more than 50 sub-platforms with the core
innovative super-trillion phage display platform, and supported by
platforms of material preparation, antibody discovery, molecule
optimization, in vitro and in vivo efficacy, production cell line
construction, upstream and downstream process development, preclinical
R&D, industrialization development, etc.
Sanyou’s proprietary platform and technology are in continuous
optimisation,we launch from time to time upgrades and new version of
services and technologies based on principles of innovation, outstanding
and reliability. The company has established friendly business
collaboration with more than 1000 pharmaceutical companies, drug R&D
institutions and diagnostics companies worldwide.